Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

NSUN2 Promotes Prostate Cancer Cell Proliferation and Migration Through m5C Modifications of YES1.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: NSUN2 Promotes Prostate Cancer Cell Proliferation and Migration Through m5C Modifications of YES1.
Συγγραφείς: Chen T; Department of Urology, The First Affliated Hospital of Chongqing Medical University, Chongqing, China.; Department of Urology, Chongqing Jiangjin District Central Hospital, Chongqing, China., Yang X; Department of Urology, Chongqing Jiangjin District Central Hospital, Chongqing, China., Su S; Department of Urology, The First Affliated Hospital of Chongqing Medical University, Chongqing, China., Wang D; Department of Urology, The First Affliated Hospital of Chongqing Medical University, Chongqing, China.
Πηγή: Molecular carcinogenesis [Mol Carcinog] 2026 Jan; Vol. 65 (1), pp. 138-145. Date of Electronic Publication: 2025 Nov 02.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8811105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2744 (Electronic) Linking ISSN: 08991987 NLM ISO Abbreviation: Mol Carcinog Subsets: MEDLINE
Imprint Name(s): Publication: <2005- > : [Hoboken, N.J.] : Wiley-Liss
Original Publication: New York : Alan R. Liss, Inc., c1988-
Ιατρικοί όροι (MeSH): Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/metabolism , Methyltransferases*/metabolism , Methyltransferases*/genetics , Proto-Oncogene Proteins c-yes*/genetics , Proto-Oncogene Proteins c-yes*/metabolism, 5-Methylcytosine/metabolism ; Humans ; Male ; Cell Proliferation ; Cell Movement ; Proto-Oncogene Mas ; Animals ; Mice ; Gene Expression Regulation, Neoplastic ; Cell Line, Tumor ; Mice, Nude ; Xenograft Model Antitumor Assays
Περίληψη: Prostate cancer (PCa) is one of the most common genitourinary malignancies in men worldwide. As a 5-methylcytosine (m5C) methyltransferase, NSUN2 has been implicated in regulating PCa progression. This study aimed to investigate the role of NSUN2 in PCa and elucidate its underlying mechanisms. The biological behaviors of PCa cells were assessed using Cell Counting Kit-8, EdU incorporation, and Transwell assays. The expression levels of relevant RNAs were determined via quantitative real-time PCR. The interaction between NSUN2 and YES proto-oncogene 1 (YES1) was examined through methylated RNA immunoprecipitation (MeRIP), RNA immunoprecipitation (RIP), and dual-luciferase reporter assays. Results showed that NSUN2 was elevated in PCa, and its downregulation suppressed cell viability, proliferation, migration, and invasion. Mechanistically, NSUN2 interacted with YES1 and stabilized its mRNA by promoting m5C modification on YES1. The oncogenic role of NSUN2 was further confirmed in xenograft models in vivo. In conclusion, our study demonstrated that NSUN2 facilitated malignant proliferation and migration of PCa cells by enhancing YES1 mRNA stability via m5C modification. These findings suggested that both NSUN2 and YES1 may serve as potential therapeutic targets for PCa, offering new strategies for treatment.
(© 2025 Wiley Periodicals LLC.)
References: M. Sekhoacha, K. Riet, P. Motloung, L. Gumenku, A. Adegoke, and S. Mashele, “Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches,” Molecules 27, no. 17 (2022): 5730.
F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.
M. Nguyen‐Nielsen and M. Borre, “Diagnostic and Therapeutic Strategies for Prostate Cancer,” Seminars in Nuclear Medicine 46, no. 6 (2016): 484–490.
S. Wasim, S. Y. Lee, and J. Kim, “Complexities of Prostate Cancer,” International Journal of Molecular Sciences 23, no. 22 (2022): 14257.
B. Yang, J. Q. Wang, Y. Tan, R. Yuan, Z. S. Chen, and C. Zou, “RNA Methylation and Cancer Treatment,” Pharmacological Research 174 (2021): 105937.
M. Han, H. Sun, Q. Zhou, et al., “Effects of RNA Methylation on Tumor Angiogenesis and Cancer Progression,” Molecular Cancer 22, no. 1 (2023): 198.
Y. Gao and J. Fang, “RNA 5‐methylcytosine Modification and Its Emerging Role as an Epitranscriptomic Mark,” RNA Biology 18, no. sup1 (2021): 117–127.
S. J. Malebary, N. Alromema, M. T. Suleman, and M. Saleem, “m5c‐iDeep: 5‐Methylcytosine Sites Identification Through Deep Learning,” Methods 230 (2024): 80–90.
Y. Motorin, F. Lyko, and M. Helm, “5‐methylcytosine in RNA: Detection, Enzymatic Formation and Biological Functions,” Nucleic Acids Research 38, no. 5 (2010): 1415–1430.
X. Yang, Y. Yang, B. F. Sun, et al., “5‐methylcytosine Promotes Mrna Export—NSUN2 as the Methyltransferase and ALYREF as an m(5)C Reader,” Cell Research 27, no. 5 (2017): 606–625.
M. Okamoto, S. Hirata, S. Sato, et al., “Frequent Increased Gene Copy Number and High Protein Expression of tRNA (cytosine‐5‐)‐methyltransferase (NSUN2) in Human Cancers,” DNA and Cell Biology 31, no. 5 (2012): 660–671.
A. Chellamuthu and S. G. Gray, “The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer,” Cells 9, no. 8 (2020): 1758.
G. Sun, S. Ma, Z. Zheng, et al., “Multi‐Omics Analysis of Expression and Prognostic Value of NSUN Members in Prostate Cancer,” Frontiers in Oncology 12 (2022): 965571.
T. Chen, Z. G. Xu, J. Luo, et al., “NSUN2 Is a Glucose Sensor Suppressing cGAS/STING to Maintain Tumorigenesis and Immunotherapy Resistance,” Cell Metabolism 35, no. 10 (2023): 1782–1798.e8.
P. Li and D. Huang, “NSUN2‐Mediated RNA Methylation: Molecular Mechanisms and Clinical Relevance in Cancer,” Cellular Signalling 123 (2024): 111375.
X. Tong, Y. Xiang, Y. Hu, et al., “NSUN2 Promotes Tumor Progression and Regulates Immune Infiltration in Nasopharyngeal Carcinoma,” Frontiers in Oncology 12 (2022): 788801.
W. Zhu, F. Wan, W. Xu, et al., “Positive Epigenetic Regulation Loop Between AR and NSUN2 Promotes Prostate Cancer Progression,” Clinical and Translational Medicine 12, no. 9 (2022): e1028.
S. J. Parsons and J. T. Parsons, “Src Family Kinases, Key Regulators of Signal Transduction,” Oncogene 23, no. 48 (2004): 7906–7909.
M. Lapouge and S. Meloche, “A Renaissance for YES in Cancer,” Oncogene 42, no. 46 (2023): 3385–3393.
E. Kook, K. S. Chun, and D. H. Kim, “Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance,” International Journal of Molecular Sciences 25, no. 3 (2024): 1450.
F. Loganzo, Jr., J. S. Dosik, Y. Zhao, et al., “Elevated Expression of Protein Tyrosine Kinase c‐Yes, but Not c‐Src, in Human Malignant Melanoma,” Oncogene 8, no. 10 (1993): 2637–2644.
K. M. Piemonte, N. N. Ingles, B. K. Weber, et al., “Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple‐Negative Breast Cancer,” Cancer Research 84, no. 21 (2024): 3556–3573.
T. Nonomura, T. Masaki, A. Morishita, et al., “Identification of c‐Yes Expression in the Nuclei of Hepatocellular Carcinoma Cells: Involvement in the Early Stages of Hepatocarcinogenesis,” International Journal of Oncology 30, no. 1 (2007): 105–111.
L. Chen, H. Cao, and Y. Feng, “MiR‐199a Suppresses Prostate Cancer Paclitaxel Resistance by Targeting YES1,” World Journal of Urology 36, no. 3 (2018): 357–365.
I. Garmendia, E. Redin, L. M. Montuenga, and A. Calvo, “YES1: A Novel Therapeutic Target and Biomarker in Cancer,” Molecular Cancer Therapeutics 21, no. 9 (2022): 1371–1380.
X. Cai, Y. Chen, D. Man, et al., “RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6‐methyladenosine Modification of YES1 mRNA in an IGF2BP1‐Dependent Manner,” Cell Death Discovery 7, no. 1 (2021): 315.
Grant Information: This study was supported by General Program of Chongqing Municipal Natural Science Foundation.
Contributed Indexing: Keywords: NSUN2; YES1; m5C modifications; prostate cancer
Substance Nomenclature: 0 (Proto-Oncogene Mas)
EC 2.1.1.- (NSUN2 protein, human)
0 (MAS1 protein, human)
EC 2.1.1.- (Methyltransferases)
EC 2.7.10.2 (Proto-Oncogene Proteins c-yes)
EC 2.7.10.2 (YES1 protein, human)
6R795CQT4H (5-Methylcytosine)
Entry Date(s): Date Created: 20251102 Date Completed: 20251229 Latest Revision: 20251229
Update Code: 20260130
DOI: 10.1002/mc.70060
PMID: 41176634
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1098-2744
DOI:10.1002/mc.70060